Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

First-line antiretroviral drug discontinuations in children.

Fortuin-de Smidt M, de Waal R, Cohen K, Technau KG, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.

PLoS One. 2017 Feb 13;12(2):e0169762. doi: 10.1371/journal.pone.0169762. eCollection 2017.

2.
3.

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team.

Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.

4.

Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Wong G, Kobinger GP.

Clin Microbiol Rev. 2015 Jul;28(3):593-601. doi: 10.1128/CMR.00014-15. Review.

5.

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, Burger D, Bernadi S, Butler K, Chiappini E, Clayden P, Della Negra M, Giacomet V, Giaquinto C, Gibb D, Galli L, Hainaut M, Koros M, Marques L, Nastouli E, Niehues T, Noguera-Julian A, Rojo P, Rudin C, Scherpbier HJ, Tudor-Williams G, Welch SB; (PENTA Steering Committee).

HIV Med. 2018 Jan;19(1):e1-e42. doi: 10.1111/hiv.12217. Epub 2015 Feb 3.

6.

Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.

Duong T, Judd A, Collins IJ, Doerholt K, Lyall H, Foster C, Butler K, Tookey P, Shingadia D, Menson E, Dunn DT, Gibb DM; Collaborative HIV Paediatric Study Steering Committee.

AIDS. 2014 Oct 23;28(16):2395-405.

7.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team.

Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.

8.

Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.

Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, Rabie H, Wood R, Cox V, Vizcaya LS, Muchiri E, Davies MA; IeDEA Southern Africa Paediatric Collaboration.

Pediatr Infect Dis J. 2014 Jun;33(6):617-22. doi: 10.1097/INF.0000000000000222.

9.

24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.

Hien H, Meda N, Diagbouga S, Zoure E, Yaméogo S, Tamboura H, Somé J, Ouiminga A, Rouet F, Drabo A, Hien A, Nicolas J, Chappuy H, Van de Perre P, Msellati P, Nacro B.

Afr Health Sci. 2013 Jun;13(2):287-94. doi: 10.4314/ahs.v13i2.13.

10.

Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R, Reubenson G, Davies MA, Coovadia A.

Pediatr Infect Dis J. 2013 Aug;32(8):851-5. doi: 10.1097/INF.0b013e31828c3738.

11.

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.

ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M, Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C, Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM.

Lancet. 2013 Apr 20;381(9875):1391-403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.

12.

Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.

Puthanakit T, Bunupuradah T, Kosalaraksa P, Vibol U, Hansudewechakul R, Ubolyam S, Suwanlerk T, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Vonthanak S, Ananworanich J, Ruxrungtham K; PREDICT Study Group.

Pediatr Infect Dis J. 2013 Mar;32(3):252-3. doi: 10.1097/INF.0b013e3182745dba.

13.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS.

Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31.

14.

Pharmacotherapy of pediatric and adolescent HIV infection.

Schuval SJ.

Ther Clin Risk Manag. 2009 Jun;5(3):469-84. Epub 2009 Jun 22.

15.

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

Rosso R, Bernardini C, Bruzzone B, Secondo G, Icardi G, Viscoli C, Di Biagio A.

Eur J Med Res. 2009 Mar 17;14(3):136-8.

Supplemental Content

Support Center